Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $84
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $44 to $84.
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $44 to $84.